메뉴 건너뛰기
The Lancet Oncology
Volumn 10, Issue 1, 2009, Pages 4-5
Sorafenib for liver cancer: the horizon broadens
Author keywords

[No Author keywords available]
Indexed keywords

DOXORUBICIN; HEPATITIS B VACCINE; PLACEBO; SORAFENIB;
EID: 57749202553     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70317-6     Document Type: Letter
Times cited : (9)
References (6)
  • 1
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 2
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double blind, placebo-controlled trial
    • Cheng A.-L., Kang Y.-K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double blind, placebo-controlled trial. Lancet Oncol 10 (2008) 25-34
    • (2008) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, A.-L.1    Kang, Y.-K.2    Chen, Z.3
  • 3
    • 7044238395 scopus 로고    scopus 로고
    • Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quallity of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18
    • Blazeby J.M., Currie E., Zee B.C., et al. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quallity of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer 40 (2004) 2439-2444
    • (2004) Eur J Cancer , vol.40 , pp. 2439-2444
    • Blazeby, J.M.1    Currie, E.2    Zee, B.C.3
  • 4
    • 44649200810 scopus 로고    scopus 로고
    • Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Proceedings of the meeting of the European Cancer Organization
    • (abstr 3500).
    • Abou-Alfa G., Johnson P., Knox J., et al. Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Proceedings of the meeting of the European Cancer Organization. European Journal of Cancer Supplements 5 (2007) 259 (abstr 3500).
    • (2007) European Journal of Cancer Supplements , vol.5 , pp. 259
    • Abou-Alfa, G.1    Johnson, P.2    Knox, J.3
  • 5
    • 0030965103 scopus 로고    scopus 로고
    • Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group
    • Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336 (1997) 1855-1859
    • (1997) N Engl J Med , vol.336 , pp. 1855-1859
    • Chang, M.H.1    Chen, C.J.2    Lai, M.S.3
  • 6
    • 19544391413 scopus 로고    scopus 로고
    • Lamivudine for patients with chronic hepatitis B and advanced liver disease
    • Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
    • (2004) N Engl J Med , vol.351 , pp. 1521-1531
    • Liaw, Y.F.1    Sung, J.J.2    Chow, W.C.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.